Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glucagon-like
100%
Potential Treatments
100%
Type 2 Diabetes Prevention
100%
Antibody Fragment
100%
Dulaglutide
100%
Type 2 Diabetes Mellitus (T2DM)
37%
Once-weekly
25%
Phase I Trial
25%
Placebo
12%
Plasma Glucose
12%
Hemoglobin A1c (HbA1c)
12%
Type 2 Diabetic Patients
12%
Clinical Trials
12%
Pharmacokinetic Study
12%
Glucose-stimulated Insulin Secretion
12%
C-peptide Levels
12%
Gastrointestinal Tract
12%
Glycated Hemoglobin A1c
12%
Dipeptidyl peptidase-4 (DPP-4)
12%
Insulinotropic Effects
12%
No-report
12%
Human IgG4
12%
Diabetes Mellitus Model
12%
Fc Fragment
12%
Expected Effect
12%
Weekly Dosing
12%
Eli Lilly
12%
Dose-dependent
12%
Insulin-like Peptide
12%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon-Like Peptide-1
100%
Dulaglutide
100%
Maturity Onset Diabetes of the Young
100%
Clinical Trial
37%
Hemoglobin A1c
25%
Insulin
25%
Side Effect
25%
Glucose
25%
Placebo
12%
C Peptide
12%
Glycosylated Hemoglobin
12%
Dipeptidyl Peptidase IV
12%
Immunoglobulin G4
12%
Immunoglobulin Fc Fragment
12%
Pharmacokinetics
12%
Biochemistry, Genetics and Molecular Biology
Glucagon-Like Peptide-1
100%
Maturity Onset Diabetes of the Young
100%
Clinical Trial
60%
Glucose Blood Level
20%
C-Peptide
20%
Body Weight
20%
Pharmacokinetics
20%
Insulin Release
20%
Glycated Hemoglobin
20%
In Vivo Study
20%
Insulin Like Activity
20%
Dipeptidyl Peptidase-4
20%
Insulin
20%
Glucose
20%